Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments

Summary

  • Cytek and 10x Genomics both offer single cell visualization tools, a growing and important field in modern medicine.
  • However, each company sees huge differences in popularity, financial performance, and valuation, leading to a significant difference in outlook.
  • This article will compare the two companies and provide my outlook on both.

Human cell, colored in imaging flow cytometry style

Dr_Microbe/iStock via Getty Images

The Growing Field of Cell Visualization and Analysis

Modern medicine now focuses on highly specific targeting principles, rather than unspecific or generalized treatments. Think monoclonal antibodies and genetic treatments such as CRISPR-Cas9 or RNA vaccines. These modern techniques require

A summary of 10x Genomics platform

A summary of TXG's Chromium platform (Yale Center for Genomic Analysis)

financial performance data of public biotech companies

Financial performance data of public biotech companies (EY)

A summary of flow cytometry devices at the facility

Rockefeller University

A summary of the genomic sequencing devices.

Rockefeller University

Cytek and 10x Genomics Revenues

Koyfin

CTKB and TXG total cash and free cash flow

Koyfin

Cytek and 10x Genomics Valuation

Koyfin

This article was written by

Hello, I am an individual investor with an interest in bringing diversification of viewpoints to stock analysis and investing. This brings to point the Japanese proverb 他山之石 -ta-zan-no-ishi- which translates to "another-mountain's-rock" and denotes the importance of diversifying the sources of your knowledge in order to gain the advantage of multiple perspectives. Further, a rock represents the foundational aspects of the world a mountain supports, signifying the importance of understanding the simple fundamentals in order to succeed. As such, I cover a wide range of assets in order to find the best of every type of investing. Please consider following so we can continue down this path of knowledge together, and hopefully, I am able to provide some novel insights for you with every article. Thanks for reading.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.